[ARCHITECT Chagas(®): a new diagnostic tool in Chagas disease]

Enferm Infecc Microbiol Clin. 2012 Oct;30(8):463-5. doi: 10.1016/j.eimc.2012.02.002. Epub 2012 Mar 23.
[Article in Spanish]

Abstract

Objective: To evaluate a new chemiluminescent microparticle immunoassay (ARCHITECT Chagas(®), Abbott).

Methods: In this study, 165 samples were tested by two different serological tests. The ARCHITECT Chagas(®) assay was performed using ARCHITECT i2000(SR) system (Abbott).

Results: The sensitivity and specificity of ARCHITECT assay was 100% and 96.6%, respectively. The concordance rate was 0.96 (95%CI: 0.92-1) for ELISA and 0.91 (95%CI: 0.85-0.97) for immunofluorescence assay (IFA).

Conclusions: The ARCHITECT Chagas(®) assay demonstrates a sensitivity and specificity similar to ELISA and IFA assays; it allows a large volume of samples to be processed with a good standardization and reproducibility, as well as an objective interpretation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Antibodies, Protozoan / blood*
  • Antigens, Protozoan / immunology
  • Chagas Disease / blood
  • Chagas Disease / diagnosis*
  • Enzyme-Linked Immunosorbent Assay
  • Fluorescent Antibody Technique, Indirect
  • Humans
  • Immunoassay / methods*
  • Luminescent Measurements*
  • Reagent Kits, Diagnostic*
  • Reproducibility of Results
  • Sampling Studies
  • Sensitivity and Specificity
  • Trypanosoma cruzi / immunology

Substances

  • Antibodies, Protozoan
  • Antigens, Protozoan
  • Reagent Kits, Diagnostic